Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer

被引：0
|
作者：
Xuetian Gao
Ling Peng
Li Zhang
Kai Huang
Cuihua Yi
Bei Li
Xue Meng
Jisheng Li
机构：
[1] Shandong Cancer Hospital and Institute,Department of Radiation Oncology
[2] Shandong First Medical University and Shandong Academy of Medical Science,Department of Respiratory Disease
[3] Zhejiang Provincial People’s Hospital,Department of Oncology
[4] Yunyang County People’s Hospital,Department of Medical Oncology
[5] Qilu Hospital,undefined
[6] Cheeloo College of Medicine,undefined
[7] Shandong University,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2022年 / 148卷
关键词：
Anlotinib; Small cell lung cancer; Efficacy; Survival; Adverse events;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2661 / 2671
页数：10
相关论文
共 50 条
  • [31] Anlotinib Versus Chemotherapy as a Third-Line or Further Treatment for Advanced Small Cell Lung Cancer
    Wang, Y.
    Ling, X.
    Cao, S.
    Li, J.
    Zhou, Y.
    Nie, W.
    Zhong, H.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S504 - S504
  • [32] Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third-or further-line treatment
    Jing Wang
    Yizhuo Zhao
    Qiming Wang
    Li Zhang
    Jianhua Shi
    Zhehai Wang
    Ying Cheng
    Jianxing He
    Yuankai Shi
    Hao Yu
    Yang Zhao
    Weiqiang Chen
    Yi Luo
    Xiuwen Wang
    Kejun Nan
    Faguang Jin
    Jian Dong
    Baolan Li
    Zhujun Liu
    Baohui Han
    Kai Li
    [J]. Cancer Biology & Medicine, 2018, (04) : 443 - 451
  • [33] Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third-or further-line treatment
    Jing Wang
    Yizhuo Zhao
    Qiming Wang
    Li Zhang
    Jianhua Shi
    Zhehai Wang
    Ying Cheng
    Jianxing He
    Yuankai Shi
    Hao Yu
    Yang Zhao
    Weiqiang Chen
    Yi Luo
    Xiuwen Wang
    Kejun Nan
    Faguang Jin
    Jian Dong
    Baolan Li
    Zhujun Liu
    Baohui Han
    Kai Li
    [J]. Cancer Biology & Medicine, 2018, 15 (04) : 443 - 451
  • [34] Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
    Jianhua Shi
    Ying Cheng
    Qiming Wang
    Kai Li
    Lin Wu
    Baohui Han
    Gongyan Chen
    Jianxing He
    Jie Wang
    Haifeng Qin
    Xiaoling Li
    [J]. Frontiers of Medicine, 2022, 16 : 766 - 772
  • [35] Effect of anlotinib as a third- or further-line therapy in advanced non-small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial
    Cheng, Ying
    Han, Baohui
    Li, Kai
    Wang, Qiming
    Zhang, Li
    Shi, Jianhua
    Wang, Zhehai
    He, Jianxing
    Shi, Yuankai
    Chen, Weiqiang
    Wang, Xiuwen
    Luo, Yi
    Nan, Kejun
    Jin, Faguang
    Li, Baolan
    Zhu, Jing
    [J]. CANCER MEDICINE, 2020, 9 (08): : 2621 - 2630
  • [36] Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
    Shi, Jianhua
    Cheng, Ying
    Wang, Qiming
    Li, Kai
    Wu, Lin
    Han, Baohui
    Chen, Gongyan
    He, Jianxing
    Wang, Jie
    Qin, Haifeng
    Li, Xiaoling
    [J]. FRONTIERS OF MEDICINE, 2022, 16 (05) : 766 - 772
  • [37] Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study
    Sun, Lei
    Zhao, Qi
    Wang, Yanning
    Wang, Yongsheng
    Zheng, Ming
    Ding, Xuansheng
    Miao, Liyun
    [J]. INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2023, 16 : 4165 - 4179
  • [38] Safety and efficacy of anlotinib hydrochloride capsules in advanced non-small-cell lung cancer: a multicenter, real-world study
    Wang, Meng
    Mao, Mengxia
    Yang, Yonghua
    Cai, Zhiqiang
    Li, Yan
    Chen, Yuanyuan
    Cai, Jun
    Ye, Qingqing
    [J]. FUTURE ONCOLOGY, 2023, 19 (25) : 1729 - 1739
  • [39] Sintilimab plus anlotinib as second or further-line therapy for small cell lung cancer: An objective performance trial.
    Ma, Shuxiang
    He, Zhen
    Wang, Lili
    Wu, Yufeng
    Yang, Sen
    Chen, Haiyang
    Wu, Yingxi
    Mo, Yuqing
    Liu, Yang
    Wang, Qiming
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] The Effect and Safety of Anlotinib as a Third Line or Further Therapy in Non-Small Cell Lung Cancer Patients With Liver Metastasis
    Shen, Y.
    Lu, J.
    Qian, J.
    Zhang, X.
    Chu, T.
    Han, B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1113 - S1113
12345